» Articles » PMID: 1371720

Allogeneic Tumor-specific Cytotoxic T Lymphocytes

Overview
Date 1992 Jan 1
PMID 1371720
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

We report the development of cytotoxic T lymphocytes specific for an allogeneic brain tumor in a rat model. DA strain cytotoxic T cell precursors stimulated by an allogeneic tumor (9L gliosarcoma) from the Fischer rat could generate a population of cytotoxic T lymphocytes that lysed the allogeneic 9L tumor but failed to lyse other targets, including Fischer concanavalin-A(ConA)-stimulated lymphoid blast targets. DA T cells depleted of reactivity to the Fischer haplotype (DA-F) retained reactivity to the 9L tumor, demonstrating that T cell precursors with specificity for normal Fischer alloantigens were not required for the generation of a response to the 9L Fischer tumor. The preferential lysis of the tumor target did not simply reflect a higher density of Fischer target antigens on the tumor than that found on normal Fischer ConA blast targets. First, the relative densities of class I antigen on the 9L tumor and normal Fischer ConA blasts were comparable. Second, cytotoxic T cells could not be generated from DA-F precursors when Fischer ConA blasts were used as stimulators. If DA-F T cells were simply responding to the higher density of Fischer antigen found on 9L tumor, it would have been expected that the ConA blasts expressing comparable levels of antigen to that found on the tumor would have generated cytotoxicity for both the 9L and ConA targets. We conclude that the cytotoxic T cells are specific for a determinant expressed only by the tumor. Such tumor-specific cytotoxic T cells could be useful in vivo for adoptive immunotherapy of brain tumors.

Citing Articles

Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Hickey M, Malone C, Erickson K, Gomez G, Young E, Liau L Am J Transl Res. 2012; 4(1):114-26.

PMID: 22347526 PMC: 3276381.


Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

Gomez G, Hickey M, Tritz R, Kruse C Gene Ther Mol Biol. 2008; 12(1):101-110.

PMID: 19066635 PMC: 2597650.


Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors.

Gomez G, Read S, Gerschenson L, Santoli D, Zweifach A, Kruse C Neuro Oncol. 2004; 6(2):83-95.

PMID: 15134622 PMC: 1871983. DOI: 10.1215/s1152851703000140.


Gamma interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes.

Paul D, Read S, Kulprathipanja N, Gomez G, Kleinschmidt-DeMasters B, Schiltz P J Neurooncol. 2003; 64(1-2):89-99.

PMID: 12952290 DOI: 10.1007/BF02700024.


Immunologic approaches to therapy for brain tumors.

Paul D, Kruse C Curr Neurol Neurosci Rep. 2002; 1(3):238-44.

PMID: 11898524 DOI: 10.1007/s11910-001-0024-8.


References
1.
Zoller M, Bellgrau D, Axberg I, Wigzell H . Natural killer cells do not belong to the recirculating lymphocyte population. Scand J Immunol. 1982; 15(2):159-67. DOI: 10.1111/j.1365-3083.1982.tb00634.x. View

2.
Medawar P . Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948; 29(1):58-69. PMC: 2073079. View

3.
Wilson D, Marshak A, Howard J . SPECIFIC positive and negative selection of rat lymphocytes reactive to strong histocompatibility antigens: activation with alloantigens in vitro and in vivo. J Immunol. 1976; 116(4):1030-40. View

4.
Heath W, Hurd M, Carbone F, Sherman L . Peptide-dependent recognition of H-2Kb by alloreactive cytotoxic T lymphocytes. Nature. 1989; 341(6244):749-52. DOI: 10.1038/341749a0. View

5.
Lafreniere R, Rosenberg S . Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol. 1985; 135(6):4273-80. View